Skip to main content

Bausch Health Companies Inc. Value Stock - Dividend - Research Selection

Bausch health

ISIN: CA0717341071 , WKN: A2JQ1X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company is engaged in the development and commercialization of a range of generics, generic and branded products, over-the-counter (OTC) products and medical devices (contact lenses, intraocular lenses, ophthalmic surgery devices and aesthetic devices). It operates through two segments: developed markets and emerging markets. The Developed Markets segment focuses on the areas of dermatology, neurology, gastrointestinal diseases and ophthalmology. The Emerging Markets segment focuses primarily on branded generics, OTC products and medical devices. The pharmaceutical products include Xifaxan, Solodyn and Glumetza. OTC products include Preservision, Biotrue and Boston. Other generics include latanoprost and metronidazole. The ophthalmic products include intraocular lenses such as Akreos, enVista, Crystalens and Trulign.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Bausch Health: Invest In The Short-Term Bonds, Not The Stock

2026-06-02
Bausch Health short-term bonds offer double-digit yields with lower default risk; post-2029 debt is riskier. Click here to read more on the BHC stock.

Bausch Health And Solta Medical Announce Thermage Awarded AAA Well-Known Trademark Certification By China Trademark Association

2026-05-28
Thermage®, a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system.LAVAL, QC, May 28, 2026

Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals

2026-05-21
Oligometastatic Disease (OMD) is a cancer stage where the disease spreads to a limited number of sites, offering a better prognosis than widespread metastasis. The OMD market is experiencing growth, driven by advances in diagnostic technologies like MRI and PET scans, and innovative treatments such as targeted therapies and immunotherapy. North America leads the market due to advanced healthcare systems, while Asia-Pacific, Latin America, and Africa offer growth opportunities. Challenges include

Bausch Health Companies Inc. (BHC) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

2026-05-20
Bausch Health Companies Inc. (BHC) RBC Capital Markets Global Healthcare Conference 2026 May 20, 2026 9:30 AM EDTCompany ParticipantsThomas Appio - CEO...

Bausch Health Announces 2026 Annual Meeting of Shareholder Results

2026-05-19
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that shareholders elected all 10 director nominees at its 2026 Annual Meeting of Shareholders ("Annual Meeting") held on May 19, 2026, including Eiry W. Roberts, M.D., who was elected as a new director. Dr. Roberts brings extensive pharmaceutical leadership experience, including expertise in clinical development, medical strategy and business development, and previously served as Chief Medical Officer of Neurocrine Biosciences, Inc

Bausch Health Companies Inc. (BHC) Presents at Barclays 30th Annual Leveraged Finance Conference 2026 Transcript

2026-05-19
Bausch Health Companies Inc. (BHC) Barclays 30th Annual Leveraged Finance Conference 2026 May 19, 2026 10:25 AM EDTCompany ParticipantsWilliam Woodfield -...

Cannabis Pharmaceuticals Business Research Report 2026: An $111.1 Billion Market by 2032 from $4.7 Billion in 2025 Featuring AbbVie, Aphria, Aurora Cannabis, Bausch Health, and Canopy Growth

2026-05-18
The cannabis pharmaceuticals market is poised for significant growth due to rising medical cannabis legalization, increasing R&D investment, and demand for alternative treatments. Key opportunities include advancements in cannabinoid research, therapeutic applications in chronic pain, neurological disorders, and mental health conditions, and the development of cannabis-based formulations driven by regulatory approvals and evolving healthcare systems. Cannabis Pharmaceuticals Market Cannabis Phar

Third Point Sells Position In Alibaba Group; Bausch Health Companies; Brookfield Corporation; Casey's General Stores; Chipotle Mexican Grill; Comfort Systems USA; Constellation Energy; CoStar Group; CSX Corporation; Danaher Corporation; Kenvue; LPL Financial; Microsoft Corporation; PG&E Corporation; Progressive Corporation; Rocket Companies; Spotify Technology; Taiwan Semiconductor Manufacturing Company; Thermo Fisher Scientific; Vistra Corp.; Wix.com.

2026-05-15
- 13F Filing

Bausch Health Companies (BHC) Price Target Decreased by 10.52% to 6.72

2026-05-14

Bausch Health to Participate in RBC Capital Markets 2026 Global Healthcare Conference

2026-05-13
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Thomas J. Appio, Chief Executive Officer, and Jean-Jacques Charhon, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the RBC Capital Markets 2026 Global Healthcare Conference in New York City on Wednesday, May 20, 2026. A live audio webcast of the event will be accessible on the Investor Relations section of Bausch Health's website.